Chemical formula: C₆H₁₁NO₂ Molecular mass: 129.157 g/mol PubChem compound: 5665
Vigabatrin is a selective irreversible inhibitor of GABA transaminase, the enzyme responsible for the breakdown of GABA (gamma aminobutyric acid). Vigabatrin increases the concentration of GABA, the major inhibitory neurotransmitter in the brain.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N03AG04 | Vigabatrin | N Nervous system → N03 Antiepileptics → N03A Antiepileptics → N03AG Fatty acid derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| KIGABEQ Soluble tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| VIGAFYDE Oral solution | MPI, US: SPL/PLR | ||
| SABRIL Film-coated tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Vigabatrin is an active ingredient of these brands:
Australia (AU)Brazil (BR)Canada (CA)Croatia (HR)Finland (FI)Hong Kong (HK)Israel (IL)Italy (IT)Japan (JP)Malta (MT)Mexico (MX)Netherlands (NL)New Zealand (NZ)Singapore (SG)South Africa (ZA)Spain (ES)Tunisia (TN)Turkey (TR)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
